Beyzanur Aktaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Beyzanur Aktaş has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Amleh
Erciyes Universitesi
1 shared publication - Guzide Satır Basaran
Department of Biochemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey
1 shared publication - Gülay Sezer
Erciyes Universitesi
1 shared publication - Merve Yıldırım
Erciyes Universitesi
1 shared publication - Muhammed İhSan Han
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey
1 shared publication
Latest Publications
- 11 May 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (3) , 812-825
miRNA regulation, antitumor activity, and molecular modeling by Naproxen-1,2,4-triazole compound in human Breast cancer
In this study, a new 1,2,4-triazole ring that has a 2-fluorophenyl ring was synthesized using (S)-Naproxen as the starting molecule. The target compound was characterized using spectroscopic methods such as FT-IR, 1H-NMR, 13C-NMR, and HR-MS. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The main aim was to show that the MDA-MB-231 cell line developed growth inhibition in a dose-dependent manner after compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at 75, 150, and 300 µM concentrations significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p could play an essential role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 and may be a biomarker for therapeutic targets in breast cancer treatment.
- 11 May 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (3) , 812-825
miRNA regulation, antitumor activity, and molecular modeling by Naproxen-1,2,4-triazole compound in human Breast cancer
In this study, a new 1,2,4-triazole ring that has a 2-fluorophenyl ring was synthesized using (S)-Naproxen as the starting molecule. The target compound was characterized using spectroscopic methods such as FT-IR, 1H-NMR, 13C-NMR, and HR-MS. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The main aim was to show that the MDA-MB-231 cell line developed growth inhibition in a dose-dependent manner after compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at 75, 150, and 300 µM concentrations significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p could play an essential role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 and may be a biomarker for therapeutic targets in breast cancer treatment.